Troy Ignelzi
2018 - scPharmaceuticals
In 2018, Troy Ignelzi earned a total compensation of $899.7K as Former Chief Financial Officer at scPharmaceuticals, a 20% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $57,927 |
|---|---|
| Option Awards | $378,371 |
| Salary | $390,450 |
| Other | $72,964 |
| Total | $899,712 |
Ignelzi received $390.5K in salary, accounting for 43% of the total pay in 2018.
Ignelzi also received $57.9K in non-equity incentive plan, $378.4K in option awards and $73K in other compensation.
Rankings
In 2018, Troy Ignelzi's compensation ranked 9,696th out of 14,244 executives tracked by ExecPay. In other words, Ignelzi earned more than 31.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,696 out of 14,244 | 32nd |
Division Manufacturing | 3,904 out of 5,765 | 32nd |
Major group Chemicals And Allied Products | 1,471 out of 2,128 | 31st |
Industry group Drugs | 1,239 out of 1,817 | 32nd |
Industry Pharmaceutical Preparations | 953 out of 1,391 | 32nd |
Source: SEC filing on April 30, 2019.
Ignelzi's colleagues
We found two more compensation records of executives who worked with Troy Ignelzi at scPharmaceuticals in 2018.
News
Karuna Therapeutics CEO Steven Paul's 2021 pay jumps 48% to $13M
April 27, 2022
Karuna Therapeutics CEO Steven Paul's 2020 pay slips 11% to $8.9M
April 27, 2021
Karuna Therapeutics CEO Steven Paul's 2019 pay jumps 932% to $10M
April 29, 2020
scPharmaceuticals CEO John Tucker's 2019 pay slips 17% to $1.2M
April 27, 2020
scPharmaceuticals CEO John Tucker's 2018 pay falls 25% to $1.5M
April 30, 2019